GlassScriptPhysician profile
Lee Jennifer Murphy
NPI 1982706412
$3,828.72
in general payments reported to CMS, 2019-2025
27 companies · $215 in 2025
The $215 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $595 · 2020: $238 · 2021: $618 · 2022: $1,077 · 2023: $662 · 2024: $424 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,300.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,367.16 | 2019-2025 | |
| Hologic Sales and Service, LLC | $438.93 | 2021-2025 | Acessa Provu System, Myosure Tissue Removal Device, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Astellas Pharma US INC | $328.21 | 2022-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $217.55 | 2019-2024 | |
| Coopersurgical, INC. | $216.73 | 2019-2025 | Paragard T 380a |
| Exeltis, USA INC. | $185.16 | 2020-2025 | Slynd |
| Agile Therapeutics, INC. | $168.17 | 2021-2024 | Twirla |
| Therapeuticsmd, INC. | $141.42 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $110.76 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $104.06 | 2023-2025 | Myfembree |
| Amag Pharmaceuticals, INC. | $91.62 | 2019-2020 | |
| Shield Therapeutics INC | $79.14 | 2022-2024 | |
| Myovant Sciences INC. | $64.06 | 2021-2022 | |
| Avion Pharmaceuticals | $47.95 | 2021-2023 | Balcoltra |
| Boston Scientific Corporation | $33.36 | 2019-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $30.69 | 2019-2021 | |
| Lupin INC. | $27.16 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $23.79 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.11 | 2022 | |
| Becton, Dickinson and Company | $20.56 | 2019 | |
| Millicent US INC | $17.70 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $17.63 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.47 | 2025 | |
| Evofem Biosciences, INC. | $15.99 | 2021 | |
| Biogen, INC. | $15.35 | 2025 | Zurzuvae |
| Hologic INC | $14.20 | 2021 | |
| Ethicon US, LLC | $12.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.